首页 > 最新文献

Annals of surgery最新文献

英文 中文
The Prognostic Impact of Minimally Invasive Esophagectomy on Survival After Esophagectomy Following a Delayed Interval After Chemoradiotherapy: A Secondary Analysis of the DICE Study. 微创食管切除术对化疗放疗延迟后食管切除术后生存期的预后影响;DICE 研究的二次分析》(The Prognostic Impact of Minimally Invasive Esophagectomy on Survival after a Delayed Interval after Chemoradiotherapy; A Secondary Analysis of DICE Study)。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-06-21 DOI: 10.1097/SLA.0000000000006411
Sheraz R Markar, Bruno Sgromo, Richard Evans, Ewen A Griffiths, Rita Alfieri, Carlo Castoro, Caroline Gronnier, Christian A Gutschow, Guillaume Piessen, Giovanni Capovilla, Peter P Grimminger, Donald E Low, James Gossage, Suzanne S Gisbertz, Jelle Ruurda, Richard van Hillegersberg, Xavier Benoit D'journo, Alexander W Phillips, Ricardo Rosati, George B Hanna, Nick Maynard, Wayne Hofstetter, Lorenzo Ferri, Mark I Berge Henegouwen, Richard Owen

Objective: To evaluate prognostic differences between minimally invasive esophagectomy (MIE) and open esophagectomy (OE) in patients with surgery after a prolonged interval (>12 wk) following chemoradiotherapy (CRT).

Background: Previously, we established that a prolonged interval after CRT before esophagectomy was associated with poorer long-term survival.

Methods: This was an international multicenter cohort study involving 17 tertiary centers, including patients who received CRT followed by surgery between 2010 and 2020. Patients undergoing MIE were defined as thoracoscopic and laparoscopic approaches.

Results: A total of 428 patients (145 MIE and 283 OE) had surgery between 12 weeks and 2 years after CRT. Significant differences were observed in American Society of Anesthesiologists grade, radiation dose, clinical T stage, and histologic subtype. There were no significant differences between the groups in age, sex, body mass index, pathologic T or N stage, resection margin status, tumor location, surgical technique, or 90-day mortality. Survival analysis showed MIE was associated with improved survival in univariate ( P =0.014), multivariate analysis after adjustment for smoking, T and N stage, and histology (HR=1.69; 95% CI: 1.14-2.5) and propensity-matched analysis ( P =0.02). Further subgroup analyses by radiation dose and interval after CRT showed survival advantage for MIE in 40 to 50 Gy dose groups (HR=1.9; 95% CI: 1.2-3.0) and in patients having surgery within 6 months of CRT (HR=1.6; 95% CI: 1.1-2.2).

Conclusions: MIE was associated with improved overall survival compared with OE in patients with a prolonged interval from CRT to surgery. The mechanism for this observed improvement in survival remains unknown, with potential hypotheses including a reduction in complications and improved functional recovery after MIE.

目的评估化放疗(CRT)后间隔时间较长(>12周)后接受手术的患者在微创食管切除术(MIE)和开放式食管切除术(OE)之间的预后差异:背景:我们曾证实,食管切除术前化疗间隔时间过长与长期生存率较低有关:这是一项国际多中心队列研究,涉及 17 个三级中心,包括在 2010-2020 年间接受 CRT 后进行手术的患者。接受MIE的患者被定义为胸腔镜和腹腔镜方法:428名患者(145名MIE患者和283名OE患者)在CRT术后12周至两年期间接受了手术。在ASA分级、放射剂量、临床T分期和组织学亚型方面观察到显著差异。组间在年龄、性别、体重指数、病理T或N分期、切除边缘状态、肿瘤位置、手术技术或90天死亡率方面无明显差异。生存分析表明,在单变量分析(P=0.014)、调整吸烟、T和N分期及组织学后的多变量分析(HR=1.69;95% CI 1.14至2.5)和倾向匹配分析(P=0.02)中,MIE与生存率的提高相关。按放射剂量和CRT后间隔时间进行的进一步亚组分析显示,MIE在40-50Gy剂量组(HR=1.9;95% CI 1.2-3.0)和CRT后6个月内接受手术的患者(HR=1.6;95% CI 1.1-2.2)中具有生存优势:结论:在从CRT到手术间隔时间较长的患者中,与OE相比,MIE与总生存率的改善相关。所观察到的生存率提高的机制尚不清楚,可能的假设包括并发症的减少和MIE后功能恢复的改善。
{"title":"The Prognostic Impact of Minimally Invasive Esophagectomy on Survival After Esophagectomy Following a Delayed Interval After Chemoradiotherapy: A Secondary Analysis of the DICE Study.","authors":"Sheraz R Markar, Bruno Sgromo, Richard Evans, Ewen A Griffiths, Rita Alfieri, Carlo Castoro, Caroline Gronnier, Christian A Gutschow, Guillaume Piessen, Giovanni Capovilla, Peter P Grimminger, Donald E Low, James Gossage, Suzanne S Gisbertz, Jelle Ruurda, Richard van Hillegersberg, Xavier Benoit D'journo, Alexander W Phillips, Ricardo Rosati, George B Hanna, Nick Maynard, Wayne Hofstetter, Lorenzo Ferri, Mark I Berge Henegouwen, Richard Owen","doi":"10.1097/SLA.0000000000006411","DOIUrl":"10.1097/SLA.0000000000006411","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate prognostic differences between minimally invasive esophagectomy (MIE) and open esophagectomy (OE) in patients with surgery after a prolonged interval (>12 wk) following chemoradiotherapy (CRT).</p><p><strong>Background: </strong>Previously, we established that a prolonged interval after CRT before esophagectomy was associated with poorer long-term survival.</p><p><strong>Methods: </strong>This was an international multicenter cohort study involving 17 tertiary centers, including patients who received CRT followed by surgery between 2010 and 2020. Patients undergoing MIE were defined as thoracoscopic and laparoscopic approaches.</p><p><strong>Results: </strong>A total of 428 patients (145 MIE and 283 OE) had surgery between 12 weeks and 2 years after CRT. Significant differences were observed in American Society of Anesthesiologists grade, radiation dose, clinical T stage, and histologic subtype. There were no significant differences between the groups in age, sex, body mass index, pathologic T or N stage, resection margin status, tumor location, surgical technique, or 90-day mortality. Survival analysis showed MIE was associated with improved survival in univariate ( P =0.014), multivariate analysis after adjustment for smoking, T and N stage, and histology (HR=1.69; 95% CI: 1.14-2.5) and propensity-matched analysis ( P =0.02). Further subgroup analyses by radiation dose and interval after CRT showed survival advantage for MIE in 40 to 50 Gy dose groups (HR=1.9; 95% CI: 1.2-3.0) and in patients having surgery within 6 months of CRT (HR=1.6; 95% CI: 1.1-2.2).</p><p><strong>Conclusions: </strong>MIE was associated with improved overall survival compared with OE in patients with a prolonged interval from CRT to surgery. The mechanism for this observed improvement in survival remains unknown, with potential hypotheses including a reduction in complications and improved functional recovery after MIE.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"650-658"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of Pancreas Transplantation At A Single Institution-50+ Years and 2500 Transplants. 一家医疗机构胰腺移植手术的发展历程--50 多年和 2,500 例移植手术。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-06-25 DOI: 10.1097/SLA.0000000000006415
Erik B Finger, Abraham J Matar, Ty B Dunn, Abhinav Humar, Angelika C Gruessner, Rainer W G Gruessner, Karthik Ramanathan, Vanessa Humphreville, Arthur J Matas, David E R Sutherland, Raja Kandaswamy

Objective: To describe the evolution of pancreas transplantation, including improved outcomes and factors associated with improved outcomes over the past 5 decades.

Background: The world's first successful pancreas transplant was performed in December 1966 at the University of Minnesota. As new modalities for diabetes treatment mature, we must carefully assess the current state of pancreas transplantation to determine its ongoing role in patient care.

Methods: A single-center retrospective review of 2500 pancreas transplants was performed over >50 years in bivariate and multivariable models. Transplants were divided into 6 eras; outcomes are presented for the entire cohort and by era.

Results: All measures of patient and graft survival improved progressively through the 6 transplant eras. The overall death-censored pancreas graft half-lives were >35 years for simultaneous pancreas and kidney (SPK), 7.1 years for pancreas after kidney (PAK), and 3.3 years for pancreas transplants alone (PTA). The 10-year death-censored pancreas graft survival rate in the most recent era was 86.9% for SPK recipients, 58.2% for PAK recipients, and 47.6% for PTA. Overall, graft loss was most influenced by patient survival in SPK transplants, whereas graft loss in PAK and PTA recipients was more often due to graft failures. Predictors of improved pancreas graft survival were primary transplants, bladder drainage of exocrine secretions, younger donor age, and shorter preservation time.

Conclusions: Pancreas outcomes have significantly improved over time through sequential, but overlapping, advances in surgical technique, immunosuppressive protocols, reduced preservation time, and the more recent reduction of immune-mediated graft loss.

摘要描述胰腺移植手术的发展历程,包括过去五十年来胰腺移植手术取得的更好疗效以及与疗效改善相关的因素:背景:1966 年 12 月,明尼苏达大学成功进行了世界上首次胰腺移植手术。随着糖尿病治疗新方法的成熟,我们必须仔细评估胰腺移植的现状,以确定其在患者护理中的持续作用:方法:采用双变量和多变量模型对超过 50 年的 2500 例胰腺移植手术进行单中心回顾性研究。移植手术分为六个年代;结果显示了整个队列和不同年代的移植结果:结果:在六个移植年代中,患者和移植物存活率的所有指标都在逐步提高。同时进行胰腺和肾脏移植(SPK)的胰腺移植物总死亡剔除(DC)半衰期大于35年,肾脏移植后进行胰腺移植(PAK)的胰腺移植物半衰期为7.1年,单独进行胰腺移植(PTA)的胰腺移植物半衰期为3.3年。在最近的年代,SPK 受者的 10 年 DC 胰腺移植物存活率为 86.9%,PAK 受者为 58.2%,PTA 为 47.6%。在SPK移植中,移植物总损失受患者存活率的影响最大,而在PAK和PTA受者中,移植物损失更多是由于移植物失败造成的。胰腺移植物存活率提高的预测因素包括初次移植、膀胱引流外分泌分泌物、供体年龄较小、保存时间较短:结论:随着时间的推移,手术技术、免疫抑制方案、保存时间的缩短以及最近免疫介导的移植物损失的减少等方面相继而又重叠地取得了进展,胰腺的预后得到了显著改善。
{"title":"Evolution of Pancreas Transplantation At A Single Institution-50+ Years and 2500 Transplants.","authors":"Erik B Finger, Abraham J Matar, Ty B Dunn, Abhinav Humar, Angelika C Gruessner, Rainer W G Gruessner, Karthik Ramanathan, Vanessa Humphreville, Arthur J Matas, David E R Sutherland, Raja Kandaswamy","doi":"10.1097/SLA.0000000000006415","DOIUrl":"10.1097/SLA.0000000000006415","url":null,"abstract":"<p><strong>Objective: </strong>To describe the evolution of pancreas transplantation, including improved outcomes and factors associated with improved outcomes over the past 5 decades.</p><p><strong>Background: </strong>The world's first successful pancreas transplant was performed in December 1966 at the University of Minnesota. As new modalities for diabetes treatment mature, we must carefully assess the current state of pancreas transplantation to determine its ongoing role in patient care.</p><p><strong>Methods: </strong>A single-center retrospective review of 2500 pancreas transplants was performed over >50 years in bivariate and multivariable models. Transplants were divided into 6 eras; outcomes are presented for the entire cohort and by era.</p><p><strong>Results: </strong>All measures of patient and graft survival improved progressively through the 6 transplant eras. The overall death-censored pancreas graft half-lives were >35 years for simultaneous pancreas and kidney (SPK), 7.1 years for pancreas after kidney (PAK), and 3.3 years for pancreas transplants alone (PTA). The 10-year death-censored pancreas graft survival rate in the most recent era was 86.9% for SPK recipients, 58.2% for PAK recipients, and 47.6% for PTA. Overall, graft loss was most influenced by patient survival in SPK transplants, whereas graft loss in PAK and PTA recipients was more often due to graft failures. Predictors of improved pancreas graft survival were primary transplants, bladder drainage of exocrine secretions, younger donor age, and shorter preservation time.</p><p><strong>Conclusions: </strong>Pancreas outcomes have significantly improved over time through sequential, but overlapping, advances in surgical technique, immunosuppressive protocols, reduced preservation time, and the more recent reduction of immune-mediated graft loss.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"604-615"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients. 早期肺癌患者立体定向体外放射治疗与微创手术的真实决策过程。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 DOI: 10.1097/SLA.0000000000006552
Stijn Vanstraelen, Kay See Tan, Prasad S Adusumilli, Manjit S Bains, Matthew J Bott, Robert J Downey, Daniel R Gomez, Katherine D Gray, James Huang, James M Isbell, Daniela Molena, Bernard J Park, Andreas Rimner, Valerie W Rusch, Narek Shaverdian, Smita Sihag, Abraham J Wu, David R Jones, Gaetano Rocco

Objective: To generate a prediction model for selection of treatment modality for early-stage non-small cell lung cancer (NSCLC).

Summary background data: Stereotactic body radiotherapy (SBRT) and minimally invasive surgery (MIS) are used in the local treatment of early-stage NSCLC. However, selection of patients for either SBRT or MIS remains challenging, due to the multitude of factors influencing the decision-making process.

Methods: We analyzed 1291 patients with clinical stage I NSCLC treated with intended MIS or SBRT from January 2020 to July 2023. A prediction model for selection for SBRT was created based on multivariable logistic regression analysis. The receiver operating characteristic curve analysis stratified the cohort into 3 treatment-related risk categories. Post-procedural outcomes, recurrence and overall survival (OS) were investigated to assess the performance of the model.

Results: In total, 1116 patients underwent MIS and 175 SBRT. The prediction model included age, performance status, previous pulmonary resection, MSK-Frailty score, FEV1 and DLCO, and demonstrated an area-under-the-curve of 0.908 (95%CI, 0.876-0.938). Based on the probability scores (n=1197), patients were stratified into a low-risk (MIS, n=970 and SBRT, n=28), intermediate-risk (MIS, n=96 and SBRT, n=53) and high-risk category (MIS, n=10 and SBRT, n=40). Treatment modality was not associated with OS (HR of SBRT, 1.67 [95%CI: 0.80-3.48]; P=0.20).

Conclusion: Clinical expertise can be translated into a robust predictive model, guiding the selection of stage I NSCLC patients for MIS versus SBRT and effectively categorizing them into three distinct risk groups. Patients in the intermediate category could benefit most from multidisciplinary evaluation.

目的:为早期非小细胞肺癌(NSCLC)治疗方式的选择建立预测模型:建立一个预测模型,用于选择早期非小细胞肺癌(NSCLC)的治疗方式:立体定向体放射治疗(SBRT)和微创手术(MIS)被用于早期非小细胞肺癌的局部治疗。然而,由于影响决策过程的因素众多,选择患者接受 SBRT 或 MIS 治疗仍具有挑战性:我们对 2020 年 1 月至 2023 年 7 月期间接受 MIS 或 SBRT 治疗的 1291 例临床 I 期 NSCLC 患者进行了分析。在多变量逻辑回归分析的基础上,建立了选择 SBRT 的预测模型。接收者操作特征曲线分析将组群分为 3 个治疗相关风险类别。为了评估该模型的性能,对手术后的结果、复发率和总生存率(OS)进行了调查:共有1116名患者接受了MIS治疗,175名患者接受了SBRT治疗。预测模型包括年龄、表现状态、既往肺切除术、MSK-Frailty 评分、FEV1 和 DLCO,其曲线下面积为 0.908(95%CI,0.876-0.938)。根据概率评分(n=1197),患者被分为低危(MIS,n=970;SBRT,n=28)、中危(MIS,n=96;SBRT,n=53)和高危(MIS,n=10;SBRT,n=40)。治疗方式与OS无关(SBRT的HR为1.67 [95%CI:0.80-3.48];P=0.20):临床专业知识可转化为强大的预测模型,指导选择 I 期 NSCLC 患者接受 MIS 或 SBRT 治疗,并有效地将患者分为三个不同的风险组别。中间组患者可从多学科评估中获益最多。
{"title":"Real-world Decision-making Process for Stereotactic Body Radiotherapy Versus Minimally Invasive Surgery in Early-stage Lung Cancer Patients.","authors":"Stijn Vanstraelen, Kay See Tan, Prasad S Adusumilli, Manjit S Bains, Matthew J Bott, Robert J Downey, Daniel R Gomez, Katherine D Gray, James Huang, James M Isbell, Daniela Molena, Bernard J Park, Andreas Rimner, Valerie W Rusch, Narek Shaverdian, Smita Sihag, Abraham J Wu, David R Jones, Gaetano Rocco","doi":"10.1097/SLA.0000000000006552","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006552","url":null,"abstract":"<p><strong>Objective: </strong>To generate a prediction model for selection of treatment modality for early-stage non-small cell lung cancer (NSCLC).</p><p><strong>Summary background data: </strong>Stereotactic body radiotherapy (SBRT) and minimally invasive surgery (MIS) are used in the local treatment of early-stage NSCLC. However, selection of patients for either SBRT or MIS remains challenging, due to the multitude of factors influencing the decision-making process.</p><p><strong>Methods: </strong>We analyzed 1291 patients with clinical stage I NSCLC treated with intended MIS or SBRT from January 2020 to July 2023. A prediction model for selection for SBRT was created based on multivariable logistic regression analysis. The receiver operating characteristic curve analysis stratified the cohort into 3 treatment-related risk categories. Post-procedural outcomes, recurrence and overall survival (OS) were investigated to assess the performance of the model.</p><p><strong>Results: </strong>In total, 1116 patients underwent MIS and 175 SBRT. The prediction model included age, performance status, previous pulmonary resection, MSK-Frailty score, FEV1 and DLCO, and demonstrated an area-under-the-curve of 0.908 (95%CI, 0.876-0.938). Based on the probability scores (n=1197), patients were stratified into a low-risk (MIS, n=970 and SBRT, n=28), intermediate-risk (MIS, n=96 and SBRT, n=53) and high-risk category (MIS, n=10 and SBRT, n=40). Treatment modality was not associated with OS (HR of SBRT, 1.67 [95%CI: 0.80-3.48]; P=0.20).</p><p><strong>Conclusion: </strong>Clinical expertise can be translated into a robust predictive model, guiding the selection of stage I NSCLC patients for MIS versus SBRT and effectively categorizing them into three distinct risk groups. Patients in the intermediate category could benefit most from multidisciplinary evaluation.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metformin Preconditioning Augments Cardiac Perfusion and Performance in a Large Animal Model of Chronic Coronary Artery Disease. 二甲双胍预处理可增强慢性冠状动脉疾病大型动物模型的心脏灌注和功能。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-07-23 DOI: 10.1097/SLA.0000000000006437
Christopher Stone, Sharif A Sabe, Dwight D Harris, Mark Broadwin, Rajeev J Kant, Meghamsh Kanuparthy, M Ruhul Abid, Frank W Sellke

Objective: To test the efficacy of metformin (MET) during the induction of coronary ischemia on myocardial performance in a large animal model of coronary artery disease (CAD) and metabolic syndrome (MS), with or without concomitant extracellular vesicular (EV) therapy.

Background: Although surgical and endovascular revascularization are durably efficacious for many patients with CAD, up to one-third are poor candidates for standard therapies. For these patients, many of whom have comorbid MS, adjunctive strategies are needed. EV therapy has shown promise in this context, but its efficacy is attenuated by MS. We investigated whether MET pretreatment could ameliorate therapeutic decrements associated with MS.

Methods: Yorkshire swine (n = 29) were provided a high-fat diet to induce MS, whereupon an ameroid constrictor was placed to induce CAD. Animals were initiated on 1000 mg oral MET or placebo; all then underwent repeat thoracotomy for intramyocardial injection of EVs or saline. Swine were maintained for 5 weeks before the acquisition of functional and perfusion data immediately before terminal myocardial harvest. Immunoblotting and immunofluorescence were performed on the most ischemic tissue from all groups.

Results: Regardless of EV administration, animals that received MET exhibited significantly improved ejection fraction, cardiac index, and contractility at rest and during rapid myocardial pacing, improved perfusion to the most ischemic myocardial region at rest and during pacing, and markedly reduced apoptosis.

Conclusions: MET administration reduced apoptotic cell death, improved perfusion, and augmented both intrinsic and load-dependent myocardial performance in a highly translatable large animal model of chronic myocardial ischemia and MS.

目的在冠状动脉疾病(CAD)和代谢综合征(MS)的大型动物模型中,测试二甲双胍在诱导冠状动脉缺血期间对心肌表现的疗效,无论是否同时进行细胞外囊泡疗法:背景:尽管外科手术和血管内再通术对许多 CAD 患者具有持久疗效,但仍有多达三分之一的患者不适合标准疗法。对于这些患者(其中许多人合并多发性硬化症),需要采取辅助治疗策略。在这种情况下,EV疗法大有可为,但其疗效会因多发性硬化症而减弱。我们研究了二甲双胍预处理是否能改善与多发性硬化症相关的治疗效果下降:约克夏猪(n=29)以高脂肪饮食诱发 MS,然后放置气门收缩器诱发 CAD。动物开始服用 1000 毫克二甲双胍或安慰剂;然后所有动物都接受了重复开胸手术,以在心肌内注射 EVs 或生理盐水。在采集终末心肌前获得功能和灌注数据之前,猪被饲养五周。对各组缺血最严重的组织进行免疫印迹和免疫荧光检测:结果:无论给予哪种 EV,接受二甲双胍治疗的动物在静息状态和快速心肌起搏时的射血分数、心脏指数和收缩力都有显著改善;静息状态和起搏时最缺血心肌区域的灌注改善;细胞凋亡明显减少:二甲双胍可减少细胞凋亡,改善灌注,并提高慢性心肌缺血和代谢综合征大型动物模型的内在和负荷依赖性心肌性能。
{"title":"Metformin Preconditioning Augments Cardiac Perfusion and Performance in a Large Animal Model of Chronic Coronary Artery Disease.","authors":"Christopher Stone, Sharif A Sabe, Dwight D Harris, Mark Broadwin, Rajeev J Kant, Meghamsh Kanuparthy, M Ruhul Abid, Frank W Sellke","doi":"10.1097/SLA.0000000000006437","DOIUrl":"10.1097/SLA.0000000000006437","url":null,"abstract":"<p><strong>Objective: </strong>To test the efficacy of metformin (MET) during the induction of coronary ischemia on myocardial performance in a large animal model of coronary artery disease (CAD) and metabolic syndrome (MS), with or without concomitant extracellular vesicular (EV) therapy.</p><p><strong>Background: </strong>Although surgical and endovascular revascularization are durably efficacious for many patients with CAD, up to one-third are poor candidates for standard therapies. For these patients, many of whom have comorbid MS, adjunctive strategies are needed. EV therapy has shown promise in this context, but its efficacy is attenuated by MS. We investigated whether MET pretreatment could ameliorate therapeutic decrements associated with MS.</p><p><strong>Methods: </strong>Yorkshire swine (n = 29) were provided a high-fat diet to induce MS, whereupon an ameroid constrictor was placed to induce CAD. Animals were initiated on 1000 mg oral MET or placebo; all then underwent repeat thoracotomy for intramyocardial injection of EVs or saline. Swine were maintained for 5 weeks before the acquisition of functional and perfusion data immediately before terminal myocardial harvest. Immunoblotting and immunofluorescence were performed on the most ischemic tissue from all groups.</p><p><strong>Results: </strong>Regardless of EV administration, animals that received MET exhibited significantly improved ejection fraction, cardiac index, and contractility at rest and during rapid myocardial pacing, improved perfusion to the most ischemic myocardial region at rest and during pacing, and markedly reduced apoptosis.</p><p><strong>Conclusions: </strong>MET administration reduced apoptotic cell death, improved perfusion, and augmented both intrinsic and load-dependent myocardial performance in a highly translatable large animal model of chronic myocardial ischemia and MS.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"547-556"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extended Pharmacologic Prophylaxis for Venous Thromboembolism After Colon Cancer Surgery Is Associated With Improved Long-term Survival: A Natural Experiment in the Chemotherapeutic Benefit of Heparin Derivatives. 结肠癌手术后静脉血栓栓塞的延长药物预防与长期生存率的提高有关:肝素衍生物化疗益处的自然实验。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-06-11 DOI: 10.1097/SLA.0000000000006376
Alexander Booth, Daniel Brinton, Colleen Donahue, Maggie Westfal, Virgilio George, Pinckney J Maxwell, Kit Simpson, David Mahvi, Thomas Curran

Objective: This large database study assessed whether extended pharmacologic prophylaxis for venous thromboembolism after colon cancer resection was associated with improved oncologic survival.

Background: Heparin derivatives may confer an antineoplastic effect via a variety of mechanisms (eg, inhibiting angiogenesis in the tumor microenvironment). Studies evaluating the oncologic benefit of heparin and its derivatives have been limited in postsurgical patients. Multiple society guidelines recommend consideration of 30-day treatment with low molecular weight heparin to reduce venous thromboembolism risk after abdominopelvic cancer surgery. However, utilization of extended prophylaxis remains low.

Methods: Surveillance, Epidemiology, and End Results-Medicare data were used to identify patients (age 65+) undergoing resection for nonmetastatic colon cancer from 2016 to 2017. The primary outcomes were overall and cancer-specific survival. Log-rank testing and multivariable Cox regression compared survival in patients who received extended prophylaxis versus those who did not in an inverse propensity treatment weighted cohort.

Results: A total of 20,102 patients were included in propensity-weighting and analyzed. Eight hundred (3.98%) received extended pharmacologic prophylaxis. Overall survival and cancer-specific survival were significantly higher in patients receiving prophylaxis on log-rank tests ( P =0.0017 overall, P =0.0200 cancer-specific). Multivariable Cox regression showed improved overall survival [adjusted hazard ratio 0.66 (0.56-0.78)] and cancer-specific survival [adjusted hazard ratio 0.56 (0.39-0.81)] with prophylaxis after controlling for patient, treatment, and hospital factors.

Conclusions: Extended pharmacologic prophylaxis after colon cancer resection was independently associated with improved overall and cancer-specific survival. These results suggest a potential antineoplastic effect from heparin derivatives when used in the context of preventing postsurgical venous thromboembolism.

目的:这项大型数据库研究评估了结肠癌切除术后延长静脉血栓栓塞的药物预防是否与提高肿瘤生存率有关:这项大型数据库研究评估了结肠癌切除术后延长静脉血栓栓塞的药物预防是否与提高肿瘤生存率有关:背景:肝素衍生物可通过多种机制(如抑制肿瘤微环境中的血管生成)产生抗肿瘤作用。评估肝素及其衍生物对手术后患者的肿瘤学益处的研究十分有限。多个学会的指南都建议考虑使用低分子量肝素进行为期 30 天的治疗,以降低腹盆腔癌症手术后的静脉血栓栓塞风险。然而,延长预防措施的使用率仍然很低:使用监测、流行病学和最终结果-医疗保险数据来识别 2016-2017 年期间接受非转移性结肠癌切除术的患者(65 岁以上)。主要结果是总生存率和癌症特异性生存率。对数秩检验和多变量 Cox 回归比较了反倾向治疗加权队列中接受延长预防治疗与未接受延长预防治疗患者的生存率。800人(3.98%)接受了延长的药物预防治疗。根据对数秩检验,接受预防治疗的患者总生存率和癌症特异性生存率明显更高(总生存率P=0.0017,癌症特异性生存率P=0.0200)。多变量考克斯回归显示,在控制了患者、治疗和医院因素后,预防性治疗可提高总生存率[aHR 0.66 (0.56-0.78)]和癌症特异性生存率[aHR 0.56 (0.39-0.81)]:结论:结肠癌切除术后延长药物预防与总生存期和癌症特异性生存期的改善密切相关。这些结果表明,肝素衍生物在预防手术后静脉血栓栓塞方面具有潜在的抗肿瘤作用。
{"title":"Extended Pharmacologic Prophylaxis for Venous Thromboembolism After Colon Cancer Surgery Is Associated With Improved Long-term Survival: A Natural Experiment in the Chemotherapeutic Benefit of Heparin Derivatives.","authors":"Alexander Booth, Daniel Brinton, Colleen Donahue, Maggie Westfal, Virgilio George, Pinckney J Maxwell, Kit Simpson, David Mahvi, Thomas Curran","doi":"10.1097/SLA.0000000000006376","DOIUrl":"10.1097/SLA.0000000000006376","url":null,"abstract":"<p><strong>Objective: </strong>This large database study assessed whether extended pharmacologic prophylaxis for venous thromboembolism after colon cancer resection was associated with improved oncologic survival.</p><p><strong>Background: </strong>Heparin derivatives may confer an antineoplastic effect via a variety of mechanisms (eg, inhibiting angiogenesis in the tumor microenvironment). Studies evaluating the oncologic benefit of heparin and its derivatives have been limited in postsurgical patients. Multiple society guidelines recommend consideration of 30-day treatment with low molecular weight heparin to reduce venous thromboembolism risk after abdominopelvic cancer surgery. However, utilization of extended prophylaxis remains low.</p><p><strong>Methods: </strong>Surveillance, Epidemiology, and End Results-Medicare data were used to identify patients (age 65+) undergoing resection for nonmetastatic colon cancer from 2016 to 2017. The primary outcomes were overall and cancer-specific survival. Log-rank testing and multivariable Cox regression compared survival in patients who received extended prophylaxis versus those who did not in an inverse propensity treatment weighted cohort.</p><p><strong>Results: </strong>A total of 20,102 patients were included in propensity-weighting and analyzed. Eight hundred (3.98%) received extended pharmacologic prophylaxis. Overall survival and cancer-specific survival were significantly higher in patients receiving prophylaxis on log-rank tests ( P =0.0017 overall, P =0.0200 cancer-specific). Multivariable Cox regression showed improved overall survival [adjusted hazard ratio 0.66 (0.56-0.78)] and cancer-specific survival [adjusted hazard ratio 0.56 (0.39-0.81)] with prophylaxis after controlling for patient, treatment, and hospital factors.</p><p><strong>Conclusions: </strong>Extended pharmacologic prophylaxis after colon cancer resection was independently associated with improved overall and cancer-specific survival. These results suggest a potential antineoplastic effect from heparin derivatives when used in the context of preventing postsurgical venous thromboembolism.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"595-603"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomical Feasibility of Endobentall Strategies for Management of Acute type A Aortic Dissection. 治疗急性 A 型主动脉夹层的内支架策略在解剖学上的可行性。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 DOI: 10.1097/SLA.0000000000006548
Aurelien Vallée, Guillaume Guimbretière, Julien Guihaire, Antoine Guery, Maira Gaillard, Le Houerou Thomas, Antoine Gaudin, Ramzi Ramadan, Deleuze Phillippe, Blandine Maurel, Jean Christian Roussel, Said Ghostine, André Vincentelli, Francis Juthier, Dominique Fabre, Jonathan Sobocinski, Stephan Haulon

Objectives: This study assesses the feasibility of acute type A dissections treatment with a dedicated aortic root endograft concept and introduces a new aortic classification.

Summary background data: Acute type A aortic dissection (ATAAD) remains a catastrophic aortic condition with perioperative mortality ranging from 12% and 20%. Total Aortic root endovascular repair, "Endobentall concept", has been explored as an alternative but only documented on case report.

Methods: Imaging study of all consecutive patients treated in three French centers were achieved. The study introduces an adapted aortic classification to report entry tear locations. Measurements included aortic annulus mensuration, coronary height, and several aortic lengths. Two treatment concepts were described "fenestrated Endobentall" and "branched Endobentall". Patients were eligible to the "fenestrated endobentall" design if their aortic root dimensions fitted the Edwards Sapien® and Corevalve Medtronic® instruction for use. Eligibility for the "branched Endobentall" required meeting the criteria for a "fenestrated Endobentall" and having a left coronary main stem length exceeding 5 mm. "Branched Endobentall" was mandatory when the entry was located in the aortic root.

Results: A total of 250 CT scans for acute type A aortic dissection were reviewed, 116 were finally included for analysis. The primary entry tear was found in the aortic root in 9% of patients, and in 31% of cases, it was located within the first centimeter distal to the sinotubular junction (STJ). 63.7% of the patients were eligible for an Endobentall procedure, even 73.3% when considering extended criterion. Fenestrated Endobentall accounted for 2/3 of cases.

Conclusion: In our study, 63.7% of patients with aortic type A dissections are deemed eligible to an "Endobentall repair", increasing to 73.3% when considering extended anatomical criteria.

目的:本研究评估了使用专用主动脉根部内移植概念治疗急性 A 型夹层的可行性,并介绍了新的主动脉分类:本研究评估了使用专用主动脉根部内移植概念治疗急性 A 型夹层的可行性,并介绍了一种新的主动脉分类方法:急性 A 型主动脉夹层(ATAAD)仍然是一种灾难性主动脉疾病,围手术期死亡率在 12% 到 20% 之间。全主动脉根部血管内修复术,即 "Endobentall 概念",已被视为一种替代方案,但只有病例报告:方法:对在法国三个中心接受治疗的所有连续患者进行影像学研究。方法:对法国三个中心接受治疗的所有连续患者进行了成像研究。研究采用了一种经过改良的主动脉分类法来报告入口撕裂位置。测量包括主动脉瓣环测量、冠状动脉高度和几个主动脉长度。研究介绍了 "栅栏式 Endobentall "和 "分枝式 Endobentall "两种治疗理念。如果患者的主动脉根部尺寸符合 Edwards Sapien® 和 Corevalve Medtronic® 的使用说明,则有资格使用 "栅栏式 Endobentall "设计。使用 "分枝式 Endobentall "的患者必须符合 "有孔 Endobentall "的标准,且左冠状动脉主干长度超过 5 毫米。如果入口位于主动脉根部,则必须使用 "分支 Endobentall":共审查了 250 例急性 A 型主动脉夹层的 CT 扫描,最终有 116 例被纳入分析范围。9%的患者在主动脉根部发现原发撕裂,31%的病例的原发撕裂位于窦管交界处(STJ)远端第一厘米处。63.7%的患者符合 Endobentall 手术的条件,如果考虑到扩展标准,这一比例甚至达到了 73.3%。结论:在我们的研究中,63.7%的主动脉A型夹层患者被认为符合 "Endobentall修复术 "的条件,如果考虑到扩展的解剖学标准,这一比例将增至73.3%。
{"title":"Anatomical Feasibility of Endobentall Strategies for Management of Acute type A Aortic Dissection.","authors":"Aurelien Vallée, Guillaume Guimbretière, Julien Guihaire, Antoine Guery, Maira Gaillard, Le Houerou Thomas, Antoine Gaudin, Ramzi Ramadan, Deleuze Phillippe, Blandine Maurel, Jean Christian Roussel, Said Ghostine, André Vincentelli, Francis Juthier, Dominique Fabre, Jonathan Sobocinski, Stephan Haulon","doi":"10.1097/SLA.0000000000006548","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006548","url":null,"abstract":"<p><strong>Objectives: </strong>This study assesses the feasibility of acute type A dissections treatment with a dedicated aortic root endograft concept and introduces a new aortic classification.</p><p><strong>Summary background data: </strong>Acute type A aortic dissection (ATAAD) remains a catastrophic aortic condition with perioperative mortality ranging from 12% and 20%. Total Aortic root endovascular repair, \"Endobentall concept\", has been explored as an alternative but only documented on case report.</p><p><strong>Methods: </strong>Imaging study of all consecutive patients treated in three French centers were achieved. The study introduces an adapted aortic classification to report entry tear locations. Measurements included aortic annulus mensuration, coronary height, and several aortic lengths. Two treatment concepts were described \"fenestrated Endobentall\" and \"branched Endobentall\". Patients were eligible to the \"fenestrated endobentall\" design if their aortic root dimensions fitted the Edwards Sapien® and Corevalve Medtronic® instruction for use. Eligibility for the \"branched Endobentall\" required meeting the criteria for a \"fenestrated Endobentall\" and having a left coronary main stem length exceeding 5 mm. \"Branched Endobentall\" was mandatory when the entry was located in the aortic root.</p><p><strong>Results: </strong>A total of 250 CT scans for acute type A aortic dissection were reviewed, 116 were finally included for analysis. The primary entry tear was found in the aortic root in 9% of patients, and in 31% of cases, it was located within the first centimeter distal to the sinotubular junction (STJ). 63.7% of the patients were eligible for an Endobentall procedure, even 73.3% when considering extended criterion. Fenestrated Endobentall accounted for 2/3 of cases.</p><p><strong>Conclusion: </strong>In our study, 63.7% of patients with aortic type A dissections are deemed eligible to an \"Endobentall repair\", increasing to 73.3% when considering extended anatomical criteria.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
For the Love of the Game: Calculating the Premium Associated With Academic Surgical Practice. 出于对游戏的热爱:计算与外科学术实践相关的溢价。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-06-25 DOI: 10.1097/SLA.0000000000006414
Emily A Grimsley, David O Anderson, Melissa A Kendall, Tyler Zander, Rajavi Parikh, Ronald J Weigel, Paul C Kuo

Objective: We sought to determine the premium associated with a career in academic surgery, as measured by compensation normalized to the work relative value unit (wRVU).

Background: An academic surgical career embodying innovation and mentorship offers intrinsic rewards but is not well monetized. We know compensation for academic surgeons is less than their nonacademic counterparts, but the value of clinical effort, as normalized to the wRVU, between academic and nonacademic surgeons has not been well characterized. Thus, we analyzed the variations in the valuation of academic and nonacademic surgical work from 2010 to 2022.

Methods: We utilized Medical Group Management Association Provider Compensation data from 2010, 2014, 2018, and 2022 to compare academic and nonacademic surgeons. We analyzed raw total cash compensation (TCC), wRVU, TCC per wRVU (TCC/wRVU), and TCC to collections (TCCtColl). We calculated collections per wRVU (Coll/wRVU). We adjusted TCC and TCCtColl for inflation using the Consumer Price Index. Linear modeling for trend analysis was performed.

Results: Compared with nonacademic, academic surgeons had lower TCC (2010: $500,415.0±23,666 vs $631,515.5±23,948.2, -21%; 2022: $564,789.8±23,993.9 vs $628,247.4±15,753.2, -10%), despite higher wRVUs (2022: 9109.4±474.9 vs 8062.7±252.7) and higher Coll/wRVU (2022: 76.68±8.15 vs 71.80±6.10). Trend analysis indicated that TCC will converge in 2038 at an estimated $660,931.

Conclusions: In 2022, academic surgeons had more clinical activity and superior organizational revenue capture, despite less total and normalized clinical compensation. On the basis of TCC/wRVUs, academia charges a premium of 16% over nonacademic surgery. However, trend analysis suggests that TCC will converge within the next 20 years.

目的:我们试图确定与外科学术生涯相关的溢价:我们试图确定与学术外科职业相关的溢价,其衡量标准是以工作相对价值单位(wRVU)归一化的报酬:背景:学术外科职业体现了创新和导师制,提供了内在回报,但并没有很好地货币化。我们知道,学术外科医生的报酬低于非学术外科医生,但学术外科医生和非学术外科医生的临床努力价值(按工作相对价值单位归一化)还没有得到很好的描述。因此,我们分析了 2010 年至 2022 年学术和非学术外科工作估值的变化:我们利用医疗集团管理协会(Medical Group Management Association)2010、2014、2018 和 2022 年的医疗机构薪酬数据,对学术和非学术外科医生进行了比较。我们分析了原始现金补偿总额 (TCC)、wRVU、每 wRVU 的 TCC (TCC/wRVU) 以及 TCC 与收款的比率 (TCCtColl)。我们计算了每 wRVU 的收款(Coll/wRVU)。我们使用消费者价格指数对 TCC 和 TCCtColl 进行了通货膨胀调整。对趋势分析进行了线性建模:结果:与非学术外科医生相比,学术外科医生的TCC较低(2010年:$500,415.0±23,666 vs. $631,515.5±23,948.2,-21%;2022年:$564,789.8±23,993.9 vs. $628,247.4±15%)。趋势分析表明,TCC 将在 2038 年趋同,估计为 660,931 美元:2022 年,学术外科医生的临床活动更多,组织收入获取能力更强,尽管临床报酬总额和归一化报酬较低。根据 TCC/wRVUs 计算,学术外科医生的收费比非学术外科医生高出 16%。然而,趋势分析表明,TCC 将在未来二十年内趋于一致。
{"title":"For the Love of the Game: Calculating the Premium Associated With Academic Surgical Practice.","authors":"Emily A Grimsley, David O Anderson, Melissa A Kendall, Tyler Zander, Rajavi Parikh, Ronald J Weigel, Paul C Kuo","doi":"10.1097/SLA.0000000000006414","DOIUrl":"10.1097/SLA.0000000000006414","url":null,"abstract":"<p><strong>Objective: </strong>We sought to determine the premium associated with a career in academic surgery, as measured by compensation normalized to the work relative value unit (wRVU).</p><p><strong>Background: </strong>An academic surgical career embodying innovation and mentorship offers intrinsic rewards but is not well monetized. We know compensation for academic surgeons is less than their nonacademic counterparts, but the value of clinical effort, as normalized to the wRVU, between academic and nonacademic surgeons has not been well characterized. Thus, we analyzed the variations in the valuation of academic and nonacademic surgical work from 2010 to 2022.</p><p><strong>Methods: </strong>We utilized Medical Group Management Association Provider Compensation data from 2010, 2014, 2018, and 2022 to compare academic and nonacademic surgeons. We analyzed raw total cash compensation (TCC), wRVU, TCC per wRVU (TCC/wRVU), and TCC to collections (TCCtColl). We calculated collections per wRVU (Coll/wRVU). We adjusted TCC and TCCtColl for inflation using the Consumer Price Index. Linear modeling for trend analysis was performed.</p><p><strong>Results: </strong>Compared with nonacademic, academic surgeons had lower TCC (2010: $500,415.0±23,666 vs $631,515.5±23,948.2, -21%; 2022: $564,789.8±23,993.9 vs $628,247.4±15,753.2, -10%), despite higher wRVUs (2022: 9109.4±474.9 vs 8062.7±252.7) and higher Coll/wRVU (2022: 76.68±8.15 vs 71.80±6.10). Trend analysis indicated that TCC will converge in 2038 at an estimated $660,931.</p><p><strong>Conclusions: </strong>In 2022, academic surgeons had more clinical activity and superior organizational revenue capture, despite less total and normalized clinical compensation. On the basis of TCC/wRVUs, academia charges a premium of 16% over nonacademic surgery. However, trend analysis suggests that TCC will converge within the next 20 years.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"640-649"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141445332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Codon-Optimized and de novo-Synthesized E-Selectin/AAV2 Dose-Response Study for Vascular Regeneration Gene Therapy. 用于血管再生基因疗法的编码优化和新合成 E-选择素/AAV2剂量反应研究
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-07-08 DOI: 10.1097/SLA.0000000000006436
Francesca A Voza, Barry J Byrne, Yulexi Y Ortiz, Yan Li, Nga Le, Lucy Osafo, Antoine C Ribieras, Hongwei Shao, Carlos Theodore Huerta, Yuntao Wei, Gustavo Falero-Diaz, Andres Franco-Bravo, Roberta M Lassance-Soares, Roberto I Vazquez-Padron, Zhao-Jun Liu, Omaida C Velazquez

Objective: This study focuses on dose-response investigation using a codon-optimized and de novo-synthesized E-Selectin/AAV2 (E-Sel/AAV2) vector in preparation for Investigational New Drug enabling of subsequent clinical studies.

Background: Gene therapy is a potential solution for patients suffering from chronic limb-threatening ischemia. Understanding the dose for effective gene delivery is crucial for future Investigational New Drug-enabling studies.

Methods: Expression of the codon-optimized E-Selectin gene was assessed by flow cytometry following in vitro cell transfection assay and RT-qPCR for murine limbs injected in vivo with AAV-m-E-Selectin (E-Sel/AAV2). Dose-response studies involved 3 cohorts of FVB/NJ mice (n=6/group) with escalating log doses of E-Selectin/AAV2 injected intramuscularly in divided aliquots, ranging from 2 × 10 9 VG to 2 × 10 11 VG, into ischemic limbs created by left femoral artery/vein ligation/excision and administration of nitric oxide synthase inhibitor, L-NAME. Limb perfusion, extent of gangrene free limb, functional limb recovery, and therapeutic angiogenesis were assessed.

Results: Codon-optimized E-Sel/AAV2 gene therapy exhibits a superior expression level than WT E-Sel/AAV2 gene therapy both in vitro and in vivo. Mice treated with a high dose (2 × 10 11 VG) of E-Sel/AAV2 showed significantly improved perfusion indices, lower Faber scores, increased running stamina, and neovascularization compared with lower doses tested with control groups, indicating a distinct dose-dependent response. No toxicity was detected in any of the animal groups studied.

Conclusions: E-Sel/AAV2 Vascular Regeneration Gene Therapy holds promise for enhancing the recovery of ischemic hindlimb perfusion and function, with the effective dose identified in this study as 2 × 10 11 VG aliquots injected intramuscularly.

研究目的本研究的重点是使用经过密码子优化和新合成的 E-选择素/AAV2(E-Sel/AAV2)载体进行剂量反应调查,为后续临床研究的新药研究(IND)做准备:背景:基因疗法是慢性肢体缺血(CLTI)患者的一种潜在解决方案。背景:基因疗法是慢性肢体缺血(CLTI)患者的潜在解决方案,了解基因有效传递的剂量对于未来的新药临床试验至关重要:方法:对体内注射 AAV-m-E-Selectin (E-Sel/AAV2)的小鼠肢体进行体外细胞转染试验和 RT-qPCR 试验后,通过流式细胞术评估了经过密码子优化的 E-Selectin 基因的表达情况。剂量反应研究涉及三组 FVB/NJ 小鼠(n=6/组),将对数剂量递增的 E-Selectin/AAV2 分成 2×109 VG 至 2×1011 VG 的等分注射到通过左股动脉/静脉结扎/切除术和一氧化氮合酶抑制剂 L-NAME 造成的缺血肢体中。对肢体灌注、无坏疽肢体范围、肢体功能恢复和治疗性血管生成进行了评估:结果:编码优化的 E-Sel/AAV2 基因疗法在体外和体内的表达水平均优于 WT E-Sel/AAV2 基因疗法。使用高剂量(2×1011 VG)E-Sel/AAV2治疗的小鼠与低剂量对照组相比,灌注指数明显改善,法布尔评分降低,跑步耐力增强,新生血管增多,表明存在明显的剂量依赖性反应。研究的所有动物组均未发现毒性:结论:E-Sel/AAV2 血管再生基因疗法(VRGT)有望促进缺血后肢灌注和功能的恢复,本研究确定的有效剂量为 IM 注射 2×1011 VG 等分注射液。
{"title":"Codon-Optimized and de novo-Synthesized E-Selectin/AAV2 Dose-Response Study for Vascular Regeneration Gene Therapy.","authors":"Francesca A Voza, Barry J Byrne, Yulexi Y Ortiz, Yan Li, Nga Le, Lucy Osafo, Antoine C Ribieras, Hongwei Shao, Carlos Theodore Huerta, Yuntao Wei, Gustavo Falero-Diaz, Andres Franco-Bravo, Roberta M Lassance-Soares, Roberto I Vazquez-Padron, Zhao-Jun Liu, Omaida C Velazquez","doi":"10.1097/SLA.0000000000006436","DOIUrl":"10.1097/SLA.0000000000006436","url":null,"abstract":"<p><strong>Objective: </strong>This study focuses on dose-response investigation using a codon-optimized and de novo-synthesized E-Selectin/AAV2 (E-Sel/AAV2) vector in preparation for Investigational New Drug enabling of subsequent clinical studies.</p><p><strong>Background: </strong>Gene therapy is a potential solution for patients suffering from chronic limb-threatening ischemia. Understanding the dose for effective gene delivery is crucial for future Investigational New Drug-enabling studies.</p><p><strong>Methods: </strong>Expression of the codon-optimized E-Selectin gene was assessed by flow cytometry following in vitro cell transfection assay and RT-qPCR for murine limbs injected in vivo with AAV-m-E-Selectin (E-Sel/AAV2). Dose-response studies involved 3 cohorts of FVB/NJ mice (n=6/group) with escalating log doses of E-Selectin/AAV2 injected intramuscularly in divided aliquots, ranging from 2 × 10 9 VG to 2 × 10 11 VG, into ischemic limbs created by left femoral artery/vein ligation/excision and administration of nitric oxide synthase inhibitor, L-NAME. Limb perfusion, extent of gangrene free limb, functional limb recovery, and therapeutic angiogenesis were assessed.</p><p><strong>Results: </strong>Codon-optimized E-Sel/AAV2 gene therapy exhibits a superior expression level than WT E-Sel/AAV2 gene therapy both in vitro and in vivo. Mice treated with a high dose (2 × 10 11 VG) of E-Sel/AAV2 showed significantly improved perfusion indices, lower Faber scores, increased running stamina, and neovascularization compared with lower doses tested with control groups, indicating a distinct dose-dependent response. No toxicity was detected in any of the animal groups studied.</p><p><strong>Conclusions: </strong>E-Sel/AAV2 Vascular Regeneration Gene Therapy holds promise for enhancing the recovery of ischemic hindlimb perfusion and function, with the effective dose identified in this study as 2 × 10 11 VG aliquots injected intramuscularly.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"570-583"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD). 通过实施手术前工具包(OPTI-Surg)改善老年癌症患者的手术护理和疗效--III 期分组随机试验的最终结果(Alliance A231601CD)。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 Epub Date: 2024-07-29 DOI: 10.1097/SLA.0000000000006458
George J Chang, Heather J Gunn, Anne K Barber, Lisa M Lowenstein, Daniel Dohan, Jeanette Broering, Travis Dockter, Angelina D Tan, Amylou Dueck, Selina Chow, Heather Neuman, Emily Finlayson

Objective: To assess the effect of a practice-level preoperative frailty screening and optimization toolkit (OPTI-Surg) on postoperative functional recovery and complications in elderly cancer patients undergoing major surgery.

Background: Frailty is common in older adults. It increases the risk of poor postoperative functional recovery and complications. The potential for a practice-level screening/optimization intervention to improve outcomes is unknown.

Methods: Thoracic, gastrointestinal, and urologic oncological surgery practices within the National Cancer Institute Community Oncology Research Program (NCORP) were randomized 1:1:1 to usual care (UC), OPTI-Surg, or OPTI-Surg with an implementation coach. OPTI-Surg consisted of the Edmonton Frail Scale and guided recommendations for referral interventions. Patients 70 years old or above undergoing curative intent surgery were eligible. The primary outcome was 8 weeks postoperative function (kcal/wk). The key secondary outcome was complications within 90 days. Mixed models were used to compare UC to the 2 OPTI-Surg arms combined.

Results: From July 2019 to September 2022, 325 patients were enrolled in 29 practices. One hundred ninety-nine (64 UC, 135 OPTI-Surg) and 279 (78 UC, 201 OPTI-Surg) were evaluable for primary and secondary analysis, respectively. UC and OPTI-Surg patients did not significantly differ in total caloric expenditure (2.2 UC, 2.0 OPTI-Surg) after adjusting for baseline function ( P =0.53). UC and OPTI-Surg patients did not significantly differ in postoperative complications (25.6% UC, 35.3% OPTI-Surg, P =0.5).

Conclusions: Frailty assessment was successfully performed, but the OPTI-Surg intervention did not improve postoperative function nor reduce postoperative complications compared with UC. Future analysis will explore practice-level factors associated with toolkit implementation and the differences between the coaching and noncoaching arms.

目的评估实践层面的术前虚弱筛查和优化工具包(OPTI-Surg)对接受大手术的老年癌症患者术后功能恢复和并发症的影响:虚弱在老年人中很常见,它会增加术后功能恢复不良和并发症的风险。实践层面的筛查/优化干预对改善预后的潜力尚不清楚:方法:在NCI社区肿瘤学研究项目(NCORP)中,胸腔、胃肠道和泌尿系统肿瘤外科医生按1:1:1的比例被随机分配到常规护理(UC)、OPTI-Surg或带实施指导的OPTI-Surg中。OPTI-Surg 包括埃德蒙顿虚弱量表和转诊干预指导建议。年龄≥70岁接受根治性手术的患者均符合条件。主要结果是术后 8 周的功能(千卡/周)。主要次要结果是 90 天内的并发症。混合模型用于比较UC与2个OPTI-Surg臂的组合:结果:从2019年7月至2022年9月,29家医疗机构共招募了325名患者。分别有 199 例(64 例 UC,135 例 OPTI-Surg)和 279 例(78 例 UC,201 例 OPTI-Surg)可进行主要和次要分析评估。在对基线功能进行调整后(P=0.53),尿毒症患者和 OPTI-Surg 患者在总热量消耗上没有明显差异(尿毒症患者 2.2,OPTI-Surg 患者 2.0)。UC和OPTI-Surg患者在术后并发症方面没有明显差异(UC为25.6%,OPTI-Surg为35.3%,P=0.5):结论:虚弱评估已成功实施,但与 UC 相比,OPTI-Surg 干预既没有改善术后功能,也没有减少术后并发症。未来的分析将探讨与工具包实施相关的实践层面因素,以及指导臂和非指导臂之间的差异。
{"title":"Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)-Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD).","authors":"George J Chang, Heather J Gunn, Anne K Barber, Lisa M Lowenstein, Daniel Dohan, Jeanette Broering, Travis Dockter, Angelina D Tan, Amylou Dueck, Selina Chow, Heather Neuman, Emily Finlayson","doi":"10.1097/SLA.0000000000006458","DOIUrl":"10.1097/SLA.0000000000006458","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effect of a practice-level preoperative frailty screening and optimization toolkit (OPTI-Surg) on postoperative functional recovery and complications in elderly cancer patients undergoing major surgery.</p><p><strong>Background: </strong>Frailty is common in older adults. It increases the risk of poor postoperative functional recovery and complications. The potential for a practice-level screening/optimization intervention to improve outcomes is unknown.</p><p><strong>Methods: </strong>Thoracic, gastrointestinal, and urologic oncological surgery practices within the National Cancer Institute Community Oncology Research Program (NCORP) were randomized 1:1:1 to usual care (UC), OPTI-Surg, or OPTI-Surg with an implementation coach. OPTI-Surg consisted of the Edmonton Frail Scale and guided recommendations for referral interventions. Patients 70 years old or above undergoing curative intent surgery were eligible. The primary outcome was 8 weeks postoperative function (kcal/wk). The key secondary outcome was complications within 90 days. Mixed models were used to compare UC to the 2 OPTI-Surg arms combined.</p><p><strong>Results: </strong>From July 2019 to September 2022, 325 patients were enrolled in 29 practices. One hundred ninety-nine (64 UC, 135 OPTI-Surg) and 279 (78 UC, 201 OPTI-Surg) were evaluable for primary and secondary analysis, respectively. UC and OPTI-Surg patients did not significantly differ in total caloric expenditure (2.2 UC, 2.0 OPTI-Surg) after adjusting for baseline function ( P =0.53). UC and OPTI-Surg patients did not significantly differ in postoperative complications (25.6% UC, 35.3% OPTI-Surg, P =0.5).</p><p><strong>Conclusions: </strong>Frailty assessment was successfully performed, but the OPTI-Surg intervention did not improve postoperative function nor reduce postoperative complications compared with UC. Future analysis will explore practice-level factors associated with toolkit implementation and the differences between the coaching and noncoaching arms.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":"623-632"},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Familiar Working Environment Influences Surgeon's Stress in the Operating Room: A Multi-Specialty Prospective Cohort Study. 熟悉的工作环境会影响外科医生在手术室的压力:一项多专科前瞻性队列研究。
IF 7.5 1区 医学 Q1 SURGERY Pub Date : 2024-10-01 DOI: 10.1097/SLA.0000000000006543
Jake A Awtry, Sarah C Skinner, Léa Pascal, Stephanie Polazzi, Jean-Christophe Lifante, Antoine Duclos

Objective: To determine the influence of operating room familiarity on surgeon stress.

Background: Regulating surgeon stress may improve patient safety. This study evaluated how assisting surgeon and operating room familiarity influence intraoperative heart rate variability among surgeons.

Methods: Attending surgeons from seven specialties within four university hospitals in France were enrolled from 11/01/20-12/31/21. Vagal tone, an indicator of stress derived from heart rate variability, was assessed during the first five minutes after incision using the root mean square of successive differences (RMSSD). Higher RMSSD values indicate greater vagal tone. Team familiarity was quantified as the cumulative time the attending and assisting surgeons had operated together in the past, while operating rooms in which the surgeon conducted >10% of their operations were termed familiar. The effect of each on the RMSSD was assessed via a linear mixed-effect model adjusting for the random effect of the surgeon and possible confounders.

Results: Overall, 643 surgeries performed by 37 surgeons were included. Median surgeon age was 49 years, 29(78.4%) were male, and 22(59.5%) were professors. Surgeons spent an average of 21.2 hours with the assisting surgeon prior to surgery and conducted 585(91.0%) of their operations in a familiar operating room. For every 10 additional hours spent operating together, ln(RMSSD) significantly increased by 0.018 (95%CI: 0.003 to 0.033, P=0.016). Familiar operating rooms also tended to increase surgeon ln(RMSSD) [0.098 (95%CI: -0.007 to 0.203, P=0.068)].

Conclusion: Familiar assisting surgeons, and potentially operating rooms, increased surgeon vagal tone. Maintaining a stable operating room environment may improve surgeon stress and patient care.

目的:确定手术室熟悉程度对外科医生压力的影响:确定手术室熟悉程度对外科医生压力的影响:背景:调节外科医生的压力可提高患者安全。本研究评估了辅助外科医生和手术室熟悉程度对外科医生术中心率变异性的影响:方法:在 11/01/20-12/31/21 期间,来自法国四所大学医院七个专业的外科医生参加了这项研究。根据心率变异性得出的压力指标--迷走神经张力,在切口后的前五分钟内使用连续差值的均方根(RMSSD)进行评估。RMSSD 值越高,迷走神经张力越强。团队熟悉度的量化标准是主刀医生和助手医生过去一起手术的累计时间,而外科医生在其中进行的手术超过 10% 的手术室被称为熟悉的手术室。通过线性混合效应模型评估了每种因素对RMSSD的影响,并调整了外科医生的随机效应和可能的混杂因素:共纳入 37 名外科医生实施的 643 例手术。外科医生年龄中位数为 49 岁,29 位(78.4%)为男性,22 位(59.5%)为教授。外科医生在手术前平均与辅助外科医生共事 21.2 小时,其中 585 例(91.0%)手术是在熟悉的手术室进行的。共同手术时间每增加 10 个小时,ln(RMSSD)就会显著增加 0.018 (95%CI: 0.003 to 0.033, P=0.016)。熟悉的手术室也倾向于增加外科医生的ln(RMSSD)[0.098 (95%CI: -0.007 to 0.203, P=0.068)]:结论:熟悉的辅助外科医生和潜在的手术室会增加外科医生的迷走神经张力。保持稳定的手术室环境可改善外科医生的压力和患者护理。
{"title":"A Familiar Working Environment Influences Surgeon's Stress in the Operating Room: A Multi-Specialty Prospective Cohort Study.","authors":"Jake A Awtry, Sarah C Skinner, Léa Pascal, Stephanie Polazzi, Jean-Christophe Lifante, Antoine Duclos","doi":"10.1097/SLA.0000000000006543","DOIUrl":"https://doi.org/10.1097/SLA.0000000000006543","url":null,"abstract":"<p><strong>Objective: </strong>To determine the influence of operating room familiarity on surgeon stress.</p><p><strong>Background: </strong>Regulating surgeon stress may improve patient safety. This study evaluated how assisting surgeon and operating room familiarity influence intraoperative heart rate variability among surgeons.</p><p><strong>Methods: </strong>Attending surgeons from seven specialties within four university hospitals in France were enrolled from 11/01/20-12/31/21. Vagal tone, an indicator of stress derived from heart rate variability, was assessed during the first five minutes after incision using the root mean square of successive differences (RMSSD). Higher RMSSD values indicate greater vagal tone. Team familiarity was quantified as the cumulative time the attending and assisting surgeons had operated together in the past, while operating rooms in which the surgeon conducted >10% of their operations were termed familiar. The effect of each on the RMSSD was assessed via a linear mixed-effect model adjusting for the random effect of the surgeon and possible confounders.</p><p><strong>Results: </strong>Overall, 643 surgeries performed by 37 surgeons were included. Median surgeon age was 49 years, 29(78.4%) were male, and 22(59.5%) were professors. Surgeons spent an average of 21.2 hours with the assisting surgeon prior to surgery and conducted 585(91.0%) of their operations in a familiar operating room. For every 10 additional hours spent operating together, ln(RMSSD) significantly increased by 0.018 (95%CI: 0.003 to 0.033, P=0.016). Familiar operating rooms also tended to increase surgeon ln(RMSSD) [0.098 (95%CI: -0.007 to 0.203, P=0.068)].</p><p><strong>Conclusion: </strong>Familiar assisting surgeons, and potentially operating rooms, increased surgeon vagal tone. Maintaining a stable operating room environment may improve surgeon stress and patient care.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":" ","pages":""},"PeriodicalIF":7.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annals of surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1